[go: up one dir, main page]

PE20190121A1 - Virus atenuados de bronquitis infecciosa - Google Patents

Virus atenuados de bronquitis infecciosa

Info

Publication number
PE20190121A1
PE20190121A1 PE2018001329A PE2018001329A PE20190121A1 PE 20190121 A1 PE20190121 A1 PE 20190121A1 PE 2018001329 A PE2018001329 A PE 2018001329A PE 2018001329 A PE2018001329 A PE 2018001329A PE 20190121 A1 PE20190121 A1 PE 20190121A1
Authority
PE
Peru
Prior art keywords
infectious bronchitis
bronchitis virus
attenuated infectious
coronavirus
attenuated
Prior art date
Application number
PE2018001329A
Other languages
English (en)
Inventor
Erica Bickerton
Sarah Keep
Paul Britton
Original Assignee
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Pirbright Inst filed Critical The Pirbright Inst
Publication of PE20190121A1 publication Critical patent/PE20190121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona un coronavirus atenuado vivo que comprende una mutacion en la proteina estructural nsp-3 y/o eliminacion de proteinas accesorias 3a y 3b. El coronavirus se puede usar como una vacuna para tratar y/o prevenir una enfermedad, tal como bronquitis infecciosa, en un paciente
PE2018001329A 2016-01-27 2017-01-26 Virus atenuados de bronquitis infecciosa PE20190121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1601498.7A GB201601498D0 (en) 2016-01-27 2016-01-27 Coronavirus

Publications (1)

Publication Number Publication Date
PE20190121A1 true PE20190121A1 (es) 2019-01-17

Family

ID=55535017

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001329A PE20190121A1 (es) 2016-01-27 2017-01-26 Virus atenuados de bronquitis infecciosa

Country Status (17)

Country Link
US (1) US11202825B2 (es)
EP (1) EP3408381B1 (es)
JP (1) JP2019503693A (es)
KR (1) KR20180104088A (es)
CN (1) CN108884447B (es)
AU (1) AU2017211507B2 (es)
BR (1) BR112018015453A2 (es)
CA (1) CA3012024A1 (es)
CL (1) CL2018001946A1 (es)
GB (1) GB201601498D0 (es)
IL (1) IL259655A (es)
MX (1) MX2018009008A (es)
PE (1) PE20190121A1 (es)
PH (1) PH12018501154A1 (es)
RU (1) RU2018130683A (es)
WO (1) WO2017129975A1 (es)
ZA (1) ZA201803700B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110592031B (zh) * 2019-09-25 2023-03-14 华南农业大学 一株S蛋白融合HiBiT的传染性支气管炎重组病毒及制备方法与应用
CN111437384A (zh) * 2020-04-07 2020-07-24 四川骋誉生物制品有限公司 用于预防covid-19的蝙蝠源性冠状病毒疫苗
BR102020019867A2 (pt) * 2020-09-28 2022-04-12 Fundacao Univ Estadual Do Ceara Funece Uso da vacina de coronavírus aviário (ibv) como modelo de imunização em mamíferos contra sars-cov 2
JP2024004496A (ja) * 2020-10-14 2024-01-17 一般財団法人阪大微生物病研究会 ノックアウトコロナウイルス
CN113308440B (zh) * 2021-05-26 2023-04-28 武汉大学 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
CN114807061A (zh) * 2021-12-22 2022-07-29 华南农业大学 鸡传染性支气管炎标记疫苗毒株及其制备方法、疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037650A (en) 1988-03-08 1991-08-06 Akzo N.V. Live combination vaccine
SK16162000A3 (sk) 1998-05-01 2001-12-03 Schering-Plough Ltd. Rekombinantný vírus exprimujúci cudziu dna kódujúcu mačací cd80, mačací ctla-4 alebo mačací cd86 a jeho použitie
ATE473274T1 (de) 2001-05-17 2010-07-15 Univ Utrecht Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
ES2333223T3 (es) 2003-03-03 2010-02-18 Intervet International B.V. Virus de la bronquitis infecciosa que contiene un gen punta modificado.
RU2253870C1 (ru) 2004-04-26 2005-06-10 Общество с ограниченной ответственностью Научно-производственное объединение "Диагностические системы" РЕКОМБИНАНТНЫЕ БЕЛКИ, СОДЕРЖАЩИЕ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ЭПИТОПЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ, И ПОСЛЕДОВАТЕЛЬНОСТИ СИНТЕТИЧЕСКИХ ГЕНОВ, КОДИРУЮЩИХ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ДЕТЕРМИНАНТЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ
KR100902510B1 (ko) * 2007-08-27 2009-06-15 삼성전자주식회사 한 개의 스위칭 소자와 한 개의 저항체를 포함하는비휘발성 메모리 장치
GB0911794D0 (en) 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein

Also Published As

Publication number Publication date
AU2017211507A1 (en) 2018-06-28
EP3408381B1 (en) 2021-06-23
PH12018501154A1 (en) 2019-01-28
IL259655A (en) 2018-07-31
BR112018015453A2 (en) 2018-12-18
JP2019503693A (ja) 2019-02-14
CL2018001946A1 (es) 2019-02-15
CN108884447A (zh) 2018-11-23
GB201601498D0 (en) 2016-03-09
CN108884447B (zh) 2022-07-26
CA3012024A1 (en) 2017-08-03
RU2018130683A (ru) 2020-02-27
RU2018130683A3 (es) 2020-04-21
US20190022214A1 (en) 2019-01-24
US11202825B2 (en) 2021-12-21
AU2017211507B2 (en) 2022-09-29
WO2017129975A1 (en) 2017-08-03
EP3408381A1 (en) 2018-12-05
ZA201803700B (en) 2022-12-21
MX2018009008A (es) 2018-11-19
KR20180104088A (ko) 2018-09-19

Similar Documents

Publication Publication Date Title
PE20190121A1 (es) Virus atenuados de bronquitis infecciosa
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX373792B (es) Coronavirus.
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
EP4477662A3 (en) Nucleic acid molecules and uses thereof
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
MX2018009917A (es) Vacuna contra el virus del zika.
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2017001279A (es) Usos y composiciones de la flagelina.
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX2019003376A (es) Tratamiento de aav de la enfermedad de huntington.
MX392779B (es) Anticuerpos anti-cd27
EA201591761A1 (ru) Композиции на основе наночастиц
EA201890527A1 (ru) Терапевтические вакцины против hpv18
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX379510B (es) Coronavirus bovino atenuado y vacunas relacionadas.
PE20190397A1 (es) Virus de enteritis de pato y usos del mismo
MX2017003262A (es) Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
PE20230495A1 (es) Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer